Advanced

Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer.

Melander, Olle LU ; Belting, Mattias LU ; Manjer, Jonas LU ; Maisel, Alan S; Hedblad, Bo LU ; Engström, Gunnar LU ; Nilsson, Peter LU ; Struck, Joachim; Hartmann, Oliver and Bergmann, Andreas, et al. (2014) In Cancer Epidemiology Biomarkers & Prevention 23(8). p.1672-1676
Abstract
Background: High fasting plasma proneurotensin concentration was associated with the development of breast cancer in the Malmö Diet and Cancer Study (MDCS). Here we aimed at replicating the initial finding in an independent second cohort. Methods: The Malmö Preventive Project (MPP) is a population study and comprised 18 240 subjects when examined 2002-2006. Of women without history of breast cancer at examination, we included all who developed breast cancer during follow-up (n=130) until December 31st 2010 and a random sample of women without breast cancer until end of follow-up (n=1439) for baseline plasma proneurotensin assessment (mean age 70.0±4.4 years). Proneurotensin was measured in fasted plasma samples and was related to the risk... (More)
Background: High fasting plasma proneurotensin concentration was associated with the development of breast cancer in the Malmö Diet and Cancer Study (MDCS). Here we aimed at replicating the initial finding in an independent second cohort. Methods: The Malmö Preventive Project (MPP) is a population study and comprised 18 240 subjects when examined 2002-2006. Of women without history of breast cancer at examination, we included all who developed breast cancer during follow-up (n=130) until December 31st 2010 and a random sample of women without breast cancer until end of follow-up (n=1439) for baseline plasma proneurotensin assessment (mean age 70.0±4.4 years). Proneurotensin was measured in fasted plasma samples and was related to the risk of later breast cancer development using multivariate logistic regression. Results: Proneurotensin (odds ratio [OR] per SD increment of log-transformed proneurotensin) was significantly related to incident breast cancer (OR, 2.09; 95% CI, 1.79-2.44; P < 0.001; adjusted for age, BMI, smoking and hormone replacement therapy). The effect estimate in MPP was larger than in the discovery cohort (MDCS) with the main difference between the two cohorts being that women of the MPP study were on the average about 10 years older and follow-up time shorter compared to the MDCS. Conclusion: As initially found in the MDCS, fasting plasma proneurotensin was significantly associated with the development of breast cancer also in the MPP study. Impact: Measurement of plasma proneurotensin warrants further investigation as a blood based marker for early breast cancer detection. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Epidemiology Biomarkers & Prevention
volume
23
issue
8
pages
1672 - 1676
publisher
American Association for Cancer Research
external identifiers
  • pmid:24925674
  • wos:000345274200024
  • scopus:84905501729
ISSN
1538-7755
DOI
10.1158/1055-9965.EPI-13-1200
language
English
LU publication?
yes
id
8c82e090-16e9-4e0d-a237-af8c4b3cf3c9 (old id 4528708)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24925674?dopt=Abstract
date added to LUP
2014-07-05 20:41:48
date last changed
2017-08-13 03:01:49
@article{8c82e090-16e9-4e0d-a237-af8c4b3cf3c9,
  abstract     = {Background: High fasting plasma proneurotensin concentration was associated with the development of breast cancer in the Malmö Diet and Cancer Study (MDCS). Here we aimed at replicating the initial finding in an independent second cohort. Methods: The Malmö Preventive Project (MPP) is a population study and comprised 18 240 subjects when examined 2002-2006. Of women without history of breast cancer at examination, we included all who developed breast cancer during follow-up (n=130) until December 31st 2010 and a random sample of women without breast cancer until end of follow-up (n=1439) for baseline plasma proneurotensin assessment (mean age 70.0±4.4 years). Proneurotensin was measured in fasted plasma samples and was related to the risk of later breast cancer development using multivariate logistic regression. Results: Proneurotensin (odds ratio [OR] per SD increment of log-transformed proneurotensin) was significantly related to incident breast cancer (OR, 2.09; 95% CI, 1.79-2.44; P &lt; 0.001; adjusted for age, BMI, smoking and hormone replacement therapy). The effect estimate in MPP was larger than in the discovery cohort (MDCS) with the main difference between the two cohorts being that women of the MPP study were on the average about 10 years older and follow-up time shorter compared to the MDCS. Conclusion: As initially found in the MDCS, fasting plasma proneurotensin was significantly associated with the development of breast cancer also in the MPP study. Impact: Measurement of plasma proneurotensin warrants further investigation as a blood based marker for early breast cancer detection.},
  author       = {Melander, Olle and Belting, Mattias and Manjer, Jonas and Maisel, Alan S and Hedblad, Bo and Engström, Gunnar and Nilsson, Peter and Struck, Joachim and Hartmann, Oliver and Bergmann, Andreas and Orho-Melander, Marju},
  issn         = {1538-7755},
  language     = {eng},
  number       = {8},
  pages        = {1672--1676},
  publisher    = {American Association for Cancer Research},
  series       = {Cancer Epidemiology Biomarkers & Prevention},
  title        = {Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer.},
  url          = {http://dx.doi.org/10.1158/1055-9965.EPI-13-1200},
  volume       = {23},
  year         = {2014},
}